Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 404 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Confirmatory Testing Clear all
Terminated Not applicable Interventional

Clinical Study of PGT-A Versus PGT-A+ERA

NCT03530254
View directory record Official record
Conditions
Infertility of Uterine Origin
Interventions
PGT-A, ERA Test
Diagnostic Test
Lead sponsor
Igenomix
Industry
Eligibility
Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Reading, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 25, 2026, 11:15 PM EDT
Recruiting No phase listed Observational

AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring

NCT07210021
View directory record Official record
Conditions
Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
Interventions
AK+ Guard™ ECG Application
Device
Lead sponsor
AccurKardia, Inc.
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 25, 2026, 11:15 PM EDT
Active, not recruiting Not applicable Interventional

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

NCT04338152
View directory record Official record
Conditions
Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis, Family
Interventions
Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 25, 2026, 11:15 PM EDT
Completed No phase listed Observational

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

NCT02580032
View directory record Official record
Conditions
Growth Disorder, Growth Hormone Deficiency in Children
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
4 Years to 13 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 25, 2026, 11:15 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748
View directory record Official record
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions
Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx)
Drug · Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Efficacy of Pediatric Lipid Screening Alerts

NCT04118348
View directory record Official record
Conditions
Hypercholesterolemia, Hypercholesterolemia, Familial, Hypercholesteremia in Children, Hyperlipidemia in Children
Interventions
Best Practice Alert, Health Maintenance Topic
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
9 Years to 11 Years
Enrollment
13,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients

NCT04421404
View directory record Official record
Conditions
COVID-19, Sars-CoV2
Interventions
COVID-19 Convalescent Plasma (CCP), Placebo
Biological
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Intraosseous Catheter Confirmation Study

NCT03908879
View directory record Official record
Conditions
Critical Illness
Interventions
Standard intraosseous (IO) catheter confirmation procedure, Color flow Doppler intraosseous (IO) catheter confirmation procedure, Pressure transduction intraosseous (IO) catheter confirmation procedure
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 25, 2026, 11:15 PM EDT
Not listed Phase 2 Interventional

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

NCT03457896
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Trastuzumab, Cetuximab, Neratinib, Guardant360 Diagnostic Test
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
48
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 25, 2026, 11:15 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

NCT05329103
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
PEEL-224, FOLF+B
Drug
Lead sponsor
Peel Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Scottsdale, Arizona • Palo Alto, California • Huntersville, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 25, 2026, 11:15 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 25, 2026, 11:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation

NCT06317701
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Hypoglossal Nerve Stimulation (HGNS)
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safer Sex Program for Young African-American Men

NCT01439503
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Trichomoniasis, Syphilis, HIV Infections
Interventions
Intervention
Behavioral
Lead sponsor
Richard Crosby
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

NCT03293290
View directory record Official record
Conditions
HIV Infections
Interventions
PrEP
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 25, 2026, 11:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuro-ocular Baselines in a Sports Setting

NCT03653936
View directory record Official record
Conditions
Wave Form Signals Coming From the Eye in a Healthy Cohort
Interventions
HITT device
Device
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
11 Years to 21 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Food Form and Fitness on Appetite and Digestion.

NCT01070199
View directory record Official record
Conditions
High and Increasing Contribution of Energy From Beverages in the Diet May Enhance Positive Energy Balance and Weight Gain
Interventions
liquid to liquid, liquid to solid, solid to liquid, solid to solid
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 25, 2026, 11:15 PM EDT
Recruiting No phase listed Observational

Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases

NCT07224724
View directory record Official record
Conditions
Colorectal Cancer Liver Metastases (CRLM), Metastatic Colorectal Carcinoma (mCRC)
Interventions
EXELION
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 11:15 PM EDT
Active, not recruiting Phase 1 Interventional

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

NCT02143466
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures

NCT01526265
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Usual Care, Individual Rewards, Fixed Deposits, Competitive Deposits (Pari-Mutuel), Collaborative Rewards
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2,185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 25, 2026, 11:15 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs

NCT04395118
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Mailed Outreach
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 25, 2026, 11:15 PM EDT
Terminated No phase listed Observational

Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients

NCT04892797
View directory record Official record
Conditions
Covid19
Interventions
Covid-19+ observational
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus

NCT02451124
View directory record Official record
Conditions
Barrett Esophagus
Interventions
non-endoscopic inflatable balloon for the esophagus, Questionnaire Administration, Laboratory Biomarker Analysis, esophagogastroduodenoscopy
Device · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 25, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Detecting Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring (CGM)

NCT03032523
View directory record Official record
Conditions
Neonatal Hypoglycemia
Interventions
Standard of care glucose test
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
Up to 7 Days
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 25, 2026, 11:15 PM EDT
Active, not recruiting No phase listed Observational

Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls

NCT01453660
View directory record Official record
Conditions
Germ Cell Cancer
Interventions
Endo-PAT2000 testing
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 25, 2026, 11:15 PM EDT